Skip to content
Blerp – Lifestyle
Author:
Pharvaris N.V.
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6, 2026
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
←
Previous Page
1
2